secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001628280-25-004293
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences CFO Yvonne Li departs; transition consultant through March 31
-------------------------------------------------------------------------------

- Yvonne Li's consulting agreement as Interim CFO expired Jan 31, 2025; she ceased as principal financial and accounting officer.
- Entered new consulting agreement on Feb 5, 2025 for transition support until March 31, 2025.
- No permanent CFO appointment announced; Li will cooperate with executive management on orderly handover.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828025004293/0001628280-25-004293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828025004293/snti-20250131.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer